However, we were assured by noting that the rate for progression of HAQ disability was similar in the ARCK clinic as in the surveys.
The observed event rate for progression of three or more steps in ETDRS score in this study was ~15% at 5 years [ 3], and was similar to the rates in the UKPDS and DCCT [ 4, 5], as described above.
The incidence rate for progression to an APRI ≥ 1.5 was 39.2 per 1000 person-visits; to an APRI ≥ 2, 29.2 per 1000 person-visits; to a clinical diagnosis of cirrhosis, 2.1 per 1000 person-visits; and to ESLD, 2.9 per 1000 person-visits.
The annualized incidence rates for progression to T2D among subjects without diabetes at baseline were 3.7%, 1.7%, and 0.9% in the placebo, 7.5/46, and 15/92 treatment groups, respectively.
Even more intriguing, hyperphosphorylation of Rb coincides with the start of MCM loading and, paradoxically, with the time in late-G1 when de novo mRNA synthesis is no longer rate limiting for progression into S-phase.
Carboplatin-based combination regimens are the backbone of treatment for those patients who have a late relapse (>12 months), producing clinical benefit with higher rates for progression-free and overall survival.
This model assumed that all patients are at risk to progress, and the relative rate of progression for each individual in each cohort was based on the transition probabilities.
This trial also found reductions in fasting glucose and fasting insulin, and resulted in a 54% and 76% (depending on the dose) reduction in the annualized incidence rate for the progression to type 2 diabetes among all patients studied [8].
In the present study, the 10-year mortality rate for the progression of MAC-LD was 4.8%, and 5-year and 10-year deterioration rates were 39.1% and 54.0%, respectively.
The presence of MCI was associated with a fivefold increased risk of incident KOA (p=0.008), with ORs of 4.59 (p=0.027) in model 1 and 4.90 (p=0.027) in model 2. We excluded 88 participants (21 men, 67 women) with a baseline KL grade of 4 at one or both knees, before estimating the cumulative rate for the progression of KOA during a 3-year follow-up.
Even more intriguing, the hyperphosphorylation of Rb also occurs when the MK population transitions to the period in late-G1 when de novo mRNA synthesis is no longer rate-limiting for progression into S-phase (i.e., at ∼8 hrs).
